Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $34.38.

Several research firms have weighed in on XNCR. Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd.

Hedge Funds Weigh In On Xencor

Several hedge funds have recently made changes to their positions in XNCR. Wellington Management Group LLP bought a new position in Xencor in the fourth quarter valued at $632,000. California State Teachers Retirement System grew its holdings in shares of Xencor by 12.1% in the 4th quarter. California State Teachers Retirement System now owns 59,130 shares of the biopharmaceutical company’s stock valued at $1,359,000 after acquiring an additional 6,376 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Xencor in the fourth quarter valued at about $101,000. GF Fund Management CO. LTD. bought a new stake in Xencor during the fourth quarter worth about $34,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Xencor during the fourth quarter valued at approximately $1,227,000.

Xencor Price Performance

Shares of XNCR opened at $12.95 on Tuesday. The stock has a market cap of $912.48 million, a P/E ratio of -4.05 and a beta of 0.74. Xencor has a 1 year low of $12.54 and a 1 year high of $27.24. The stock’s 50-day moving average price is $16.22 and its two-hundred day moving average price is $20.30. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, equities analysts predict that Xencor will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.